These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 34554559)
41. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: potential allies in the COVID-19 pandemic instead of a threat? Simko F; Baka T Clin Sci (Lond); 2021 Apr; 135(8):1009-1014. PubMed ID: 33881142 [TBL] [Abstract][Full Text] [Related]
42. The Correlation Between Immune Invasion and SARS-COV-2 Entry Protein ADAM17 in Cancer Patients by Bioinformatic Analysis. Wang K; Deng H; Song B; He J; Liu S; Fu J; Zhang L; Li D; Balaji KS; Mei Z; Cheng J; Fu J Front Immunol; 2022; 13():923516. PubMed ID: 35720350 [TBL] [Abstract][Full Text] [Related]
43. [Effect of components of the renin-angiotensin system, rs2106809 polymorphism of the Zuraeva ZT; Vikulova OK; Malysheva NM; Nikankina LV; Zaytceva NV; Sukhareva OY; Shamhalova MS; Shestakova MV; Mokrysheva NG Probl Endokrinol (Mosk); 2023 Aug; 69(4):21-31. PubMed ID: 37694864 [TBL] [Abstract][Full Text] [Related]
44. SARS-CoV-2 Infections and ACE2: Clinical Outcomes Linked With Increased Morbidity and Mortality in Individuals With Diabetes. Obukhov AG; Stevens BR; Prasad R; Li Calzi S; Boulton ME; Raizada MK; Oudit GY; Grant MB Diabetes; 2020 Sep; 69(9):1875-1886. PubMed ID: 32669391 [TBL] [Abstract][Full Text] [Related]
45. Going viral in the islet: mediators of SARS-CoV-2 entry beyond ACE2. Rangu R; Wander PL; Barrow BM; Zraika S J Mol Endocrinol; 2022 Jun; 69(2):R63-R79. PubMed ID: 35521990 [TBL] [Abstract][Full Text] [Related]
46. The renin-angiotensin system - a therapeutic target in COVID-19? Sturrock BR; Milne KM; Chevassut TJ Clin Med (Lond); 2020 Jul; 20(4):e72-e75. PubMed ID: 32414711 [TBL] [Abstract][Full Text] [Related]
47. The spike effect of acute respiratory syndrome coronavirus 2 and coronavirus disease 2019 vaccines on blood pressure. Angeli F; Zappa M; Reboldi G; Gentile G; Trapasso M; Spanevello A; Verdecchia P Eur J Intern Med; 2023 Mar; 109():12-21. PubMed ID: 36528504 [TBL] [Abstract][Full Text] [Related]
48. Multifunctional angiotensin converting enzyme 2, the SARS-CoV-2 entry receptor, and critical appraisal of its role in acute lung injury. Oz M; Lorke DE Biomed Pharmacother; 2021 Apr; 136():111193. PubMed ID: 33461019 [TBL] [Abstract][Full Text] [Related]
49. Novel Molecular Evidence Related to COVID-19 in Patients with Diabetes Mellitus. Liao YH; Zheng JQ; Zheng CM; Lu KC; Chao YC J Clin Med; 2020 Dec; 9(12):. PubMed ID: 33297431 [TBL] [Abstract][Full Text] [Related]
50. Cardiac and Renal SARS-CoV-2 Viral Entry Protein Regulation by Androgens and Diet: Implications for Polycystic Ovary Syndrome and COVID-19. Rezq S; Huffman AM; Basnet J; Yanes Cardozo LL; Romero DG Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575910 [TBL] [Abstract][Full Text] [Related]
51. Alpha-1-antitrypsin: A possible host protective factor against Covid-19. de Loyola MB; Dos Reis TTA; de Oliveira GXLM; da Fonseca Palmeira J; Argañaraz GA; Argañaraz ER Rev Med Virol; 2021 Mar; 31(2):e2157. PubMed ID: 32844538 [TBL] [Abstract][Full Text] [Related]
52. SARS-CoV-2 cell entry receptor ACE2 mediated endothelial dysfunction leads to vascular thrombosis in COVID-19 patients. Kumar A; Narayan RK; Kumari C; Faiq MA; Kulandhasamy M; Kant K; Pareek V Med Hypotheses; 2020 Dec; 145():110320. PubMed ID: 33032170 [TBL] [Abstract][Full Text] [Related]
53. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. Verdecchia P; Cavallini C; Spanevello A; Angeli F Eur J Intern Med; 2020 Jun; 76():14-20. PubMed ID: 32336612 [TBL] [Abstract][Full Text] [Related]
54. [ACE-inhibitors, angiotensin receptor blockers and severe acute respiratory syndrome caused by coronavirus]. Verdecchia P; Reboldi G; Cavallini C; Mazzotta G; Angeli F G Ital Cardiol (Rome); 2020 May; 21(5):321-327. PubMed ID: 32310915 [TBL] [Abstract][Full Text] [Related]
56. Assessing COVID-19 susceptibility through analysis of the genetic and epigenetic diversity of ACE2-mediated SARS-CoV-2 entry. Ragia G; Manolopoulos VG Pharmacogenomics; 2020 Dec; 21(18):1311-1329. PubMed ID: 33243086 [TBL] [Abstract][Full Text] [Related]
57. Hypothesis for renin-angiotensin inhibitor mitigation of COVID-19. Sackin H Med Hypotheses; 2021 Jul; 152():110609. PubMed ID: 34048987 [TBL] [Abstract][Full Text] [Related]
58. COVID-19, ACE2, and the cardiovascular consequences. South AM; Diz DI; Chappell MC Am J Physiol Heart Circ Physiol; 2020 May; 318(5):H1084-H1090. PubMed ID: 32228252 [TBL] [Abstract][Full Text] [Related]
59. Hypertension and COVID-19: Current Evidence and Perspectives. Gallo G; Calvez V; Savoia C High Blood Press Cardiovasc Prev; 2022 Mar; 29(2):115-123. PubMed ID: 35184271 [TBL] [Abstract][Full Text] [Related]
60. COVID-19 and Diabetes Mellitus: Potential Metabolic Associations. da Silva PHA; Garcia AS; Alves FA; Dos Santos ALS; Sodré CL Curr Top Med Chem; 2021; 21(11):929-936. PubMed ID: 34126900 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]